Regeneron's Strategic Gamble: Reviving 23andMe’s Genetic Legacy Podcast Por arte de portada

Regeneron's Strategic Gamble: Reviving 23andMe’s Genetic Legacy

Regeneron's Strategic Gamble: Reviving 23andMe’s Genetic Legacy

Escúchala gratis

Ver detalles del espectáculo

Acerca de esta escucha

 Welcome to Business Insights Daily, I’m your host, Seshank. Today we’re exploring a fascinating acquisition in the biotech world: Regeneron Pharmaceuticals is buying the embattled consumer genetics company 23andMe for $256 million following a court-supervised bankruptcy auction. It’s a deal that revives a once high-flying pioneer of personal genomics, but also raises key questions about data privacy, value creation, and the future of personalized medicine. Let’s dive in.
adbl_web_global_use_to_activate_T1_webcro805_stickypopup
Todavía no hay opiniones